Get notified when TSHA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $4.75 Per Share (new) — New investors pay $6.00 per share while the as-adjusted net tangible book value is only $1.25, resulting in immediate dilution of $4.75 per share.
Taysha Gene Therapies prices $195M primary offering at $6.00/share; net proceeds $187.4M
Filed June 25, 2026 · ~1 min read
Key Changes
-
high
Taysha is selling 32.5M shares at $6.00 each, plus pre-funded warrants for up to 833,333 shares at $5.999, raising $195.0M gross before fees.
The Offering verify on EDGAR → -
high
Net proceeds to the company are $187.4M after underwriting discounts and expenses; the company receives all proceeds as this is a primary offering.
Use of Proceeds verify on EDGAR → -
high
Proceeds will fund TSHA-102 for Rett syndrome through regulatory, manufacturing, and potential launch, plus other pipeline work; cash runway into 2H 2028.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAIC 10-Q) is open in full — no account needed.
Partner
Trade TSHA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify